LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Fulcrum Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERFULC
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / FULC COVERAGE

What’s moving Fulcrum Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) of an Ongoing Investigation Into Potential Securities Law Violations

Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) of an Ongoing Investigation Into Potential Securities Law Violations

The story matters when it changes Fulcrum Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)

The story matters when it changes Fulcrum Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

The story matters when it changes Fulcrum Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review

Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review

The story matters when it changes Fulcrum Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Fulcrum Therapeutics, Inc. Scheduled to Release Q4 and Full Year 2024 Financial Results on February 25, 2025

Fulcrum Therapeutics, Inc. Scheduled to Release Q4 and Full Year 2024 Financial Results on February 25, 2025

The story matters when it changes Fulcrum Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
06
Fulcrum Therapeutics, Inc. (FULC) Is Up 7.55% in One Week: What You Should Know

Fulcrum Therapeutics, Inc. (FULC) Is Up 7.55% in One Week: What You Should Know

The story matters when it changes Fulcrum Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
07
Fulcrum Therapeutics, Inc. (FULC) Class Action Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. (FULC) Class Action Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Fulcrum Therapeutics, Inc.

The development tests whether Fulcrum Therapeutics, Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest FULC filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-07-30 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-04-27 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-02-24 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-25 · Period 2026-06-24SEC ↗8-KMaterial company eventFiled 2026-06-11 · Period 2026-06-05SEC ↗8-KMaterial company eventFiled 2026-06-04 · Period 2026-05-31SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-30 · Period 2026-06-24SEC ↗SCHEDULE 13GOfficial SEC filingFiled 2026-08-03SEC ↗
EARNINGS / QUARTERLY TRACKER

Fulcrum Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.